Heron Therapeutics (HRTX) Misses Q2 EPS by 13c; provides corporate update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- Goldman data shows hedge funds cut leverage at fastest pace since March
Tweet
Share
E-mailGet Alerts HRTX Hot Sheet
Join SI Premium – FREE
Heron Therapeutics (NASDAQ: HRTX) reported Q2 EPS of ($0.35), $0.13 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $31.76 million versus the consensus estimate of $31.7 million.
Reiterating full-year net product sales guidance for the oncology care franchise of $99-$103 million
For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- Upstart Holdings (UPST) Tops Q3 EPS by 12c ; Offers Guidance
- Sysco Corp. (SYY) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
